Daré Bioscience, Inc. (DARE)

Market Cap	26.29M
Revenue (ttm)	25,909
Net Income (ttm)	-1.68M
Shares Out	8.85M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,456
Open	2.880
Previous Close	2.880
Day's Range	2.860 - 2.970
52-Week Range	2.670 - 6.240
Beta	1.20
Analysts	Strong Buy
Price Target	12.50 (+320.88%)
Earnings Date	May 13, 2025

About DARE

Daré Bioscience, Inc., a biopharmaceutical company, develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-H...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Sabrina Johnson
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: DARE
• Website: https://darebioscience.com

Financial Performance

In 2024, Daré Bioscience's revenue was $9,784, a decrease of -99.65% compared to the previous year's $2.81 million. Losses were -$4.05 million, -86.56% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 320.88% from the latest price.

Price Target

$12.5

(320.88% upside)

Analyst Consensus: Strong Buy